LY6D and fatty liver disease: To determine whether Ly6d inhibition could suppress hepatic steatosis in vitro, we compared lipid accumulation in AML12 cells treated with Ly6d-specific short interfering RNA (KD cells) and those treated with nontargeting short interfering RNA (control cells).